The Wall Street Journal
A new skin-cancer treatment that promises to shrink tumors and prolong the lives of patients with a particular genetic mutation won speedy approval that signals U.S. regulators' enthusiasm for such targeted therapies.
Vemurafenib, from Roche Holding AG and Daiichi Sankyo Co., belongs to an emerging class of treatments that targets the molecular underpinnings of the cancer. These therapies offer the opportunity for significantly more effective treatment for patients who test positive for a genetic mutation driving the proliferation of their cancer cells. Patients would take the drugs only after a test showed they have the mutation... Read More